Abiopharma

🔍 PAGLIUCA STEPHEN G (Director)

Company: Norwegian Cruise Line Holdings Ltd. (NCLH)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 695,000 shares of Common Stock at $18.16 per share (Direct)
  Date: 2026-06-01 | Code: P | equity_swap_involved: 0 | shares_owned_after: 703,912.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 685,000 shares of Common Stock at $18.06 per share (Direct)
  Date: 2026-06-02 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,388,912.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $17.94 to $18.45, inclusive. The reporting person undertakes to provide to Norwegian Cruise Line Holdings Ltd. ("NCLH"), any security holder of NCLH, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).
• F2: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $17.81 to $18.22, inclusive. The reporting person undertakes to provide to NCLH, any security holder of NCLH, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).